FLT3 and neoplasm: To test the tumour‐suppressive efficacy of CD33‐targeting RBCEVs loaded FLT3‐ITD ASO in vivo, AML‐xenografted mice were generated by injecting MOLM13‐Luc‐GFP cells as described above (Figure 5D).